Parecer de pré-exame
#6.23
08/16/2022
RPI 2693
Application data
Number
112020006892Type
Filing
Publication
PCT
US2018055354 The INPI issued a technical opinion on patentability. The applicant must respond for examination to continue.
Latest action published by the INPI: 08/16/2022. We update with every new RPI gazette, published weekly.
Applicants
SEAGEN INC.
US
SEATTLE GENETICS, INC.
US
Inventors
N. J. (pessoa física)
US
T. M. (pessoa física)
US
IPC Classification
Priority claims
US
62/570,901 · 10/11/2017
US
62/580,267 · 11/01/2017
US
62/639,308 · 03/06/2018
US
62/764,805 · 08/16/2018
Abstract
A presente invenção refere-se, em geral, a métodos para melhorar eventos adversos em sujeitos recebendo tratamento com um conjugado de anticorpo anti-CD30 fármaco, opcionalmente também recebendo quimioterapia associada. Os eventos adversos incluem neuropatia periférica e neutropenia.
Publications in the Brazilian Industrial Property Gazette (RPI).
#6.23
08/16/2022
RPI 2693
#25.4
03/22/2022
RPI 2672
#15.35
11/23/2021
RPI 2655
#1.3
10/06/2020
RPI 2596
#1.1
09/15/2020
RPI 2593
From the same holder
Same category
Patent monitoring
Receive alerts on INPI events, decisions, and expiry dates for your portfolio.